|
India News Releases
|
(India.CityRegions.Com, October 04, 2017 ) ReportsWeb.com published “Hepatitis A Virus Cellular Receptor 2 - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1) -mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6. For more information about this report: http://www.reportsweb.com/hepatitis-a-virus-cellular-receptor-2-pipeline-review-h1-2017 Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 6 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Colon Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Renal Cell Carcinoma. Report Scope - The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834414/sample Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Chipscreen Biosciences Ltd, H1 2017 Pipeline by CJ HealthCare Corp, H1 2017 Pipeline by Gilead Sciences Inc, H1 2017 Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Top 10 Indications, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Inquire before Buying at http://www.reportsweb.com/buy&RW0001834414/buy/3500 Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|